• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
In conclusion, this post-hoc simulation of dabigatran usage based on RE-LY trial dataset indicates that "EU label simulated dabigatran treatment" may be associated with superior efficacy and safety compared to warfarin, and are in support of the EU label and the 2012 European Society of Cardiology AF guideline recommendations. Thus, adherence to European label/guideline use results in a clinically relevant benefit for dabigatran over warfarin, for both efficacy and safety. PMID: 24326736 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 11, 2013 Category: Hematology Authors: Lip GY, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S Tags: Thromb Haemost Source Type: research

Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation. The Loire Valley Atrial Fibrillation Project.
In conclusion, composite risk scores did not significantly improve risk prediction of endpoints in patients with NVAF, regardless of how endpoints were defined. This would support individualised prediction of IS/TE and bleeding separately using different separate risk prediction tools, and not the use of composite scores or endpoints for everyday 'real world' clinical practice, to guide decisions on thromboprophylaxis. PMID: 24452108 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 23, 2014 Category: Hematology Authors: Banerjee A, Fauchier L, Bernard-Brunet A, Clementy N, Lip GY Tags: Thromb Haemost Source Type: research

Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-AF study.
CONCLUSION: If anything, despite its early termination the idrabiotaparinux regimen studied suggested a comparable efficacy to dose-adjusted warfarin, with a lower bleeding risk. This article is protected by copyright. All rights reserved. PMID: 24597472 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 5, 2014 Category: Hematology Authors: Buller HR, Halperin J, Hankey GJ, Pillion G, Prins MH, Raskob GE Tags: J Thromb Haemost Source Type: research

Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients with an elective surgery or procedure. Substudy of the RE-LY trial.
In conclusion, in patients who interrupted dabigatran or warfarin for a surgery/procedure in the RE-LY trial, use of bridging anticoagulation appeared to increase the risk for major bleeding irrespective of dabigatran or warfarin interruption. PMID: 25472710 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 4, 2014 Category: Hematology Authors: Douketis JD, Healey JS, Brueckmann M, Eikelboom JW, Ezekowitz MD, Fraessdorf M, Noack H, Oldgren J, Reilly P, Spyropoulos AC, Wallentin L, Connolly SJ Tags: Thromb Haemost Source Type: research

Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: Insights form the RE-LY trial.
CONCLUSIONS: Anemia is associated with a raised risk of thromboembolic events, bleeding complications and mortality in anticoagulated patients with AF. These findings suggest that patients with anemia should be monitored closely during all types of anticoagulant treatment. This article is protected by copyright. All rights reserved. PMID: 25683276 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - February 13, 2015 Category: Hematology Authors: Westenbrink BD, Alings M, Connolly SJ, Eikelboom J, Ezekowitz MD, Oldgren J, Yang S, Pongue J, Yusuf S, Wallentin L, van Gilst WH Tags: J Thromb Haemost Source Type: research

Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
Abstract The effectiveness and safety of dabigatran for stroke prevention in atrial fibrillation (SPAF) demonstrated in RE-LY needs to be confirmed in daily care. To evaluate treatment persistence, effectiveness and safety of dabigatran therapy in SPAF patients in daily care, we used data from an ongoing, prospective, non-interventional registry of more than 2,500 patients on novel oral anticoagulants in daily care. Between October 1, 2011 and February 28, 2013, a total of 341 SPAF patients receiving dabigatran were enrolled. The combined endpoint of stroke/transient ischaemic attack/systemic embolism occurred at ...
Source: Thrombosis and Haemostasis - March 5, 2015 Category: Hematology Authors: Beyer-Westendorf J, Ebertz F, Förster K, Gelbricht V, Michalski F, Köhler C, Werth S, Endig H, Pannach S, Tittl L, Sahin K, Daschkow K, Weiss N Tags: Thromb Haemost Source Type: research

Prevalence and risk factors of retinal vein occlusion: the Gutenberg Health Study.
CONCLUSIONS: The prevalence of RVO in this German population was 0.4% and males were 1.7 times more frequently affected than females. CRVO was associated with higher age and a family history of stroke, and BRVO with arterial hypertension and atrial fibrillation. This article is protected by copyright. All rights reserved. PMID: 25894549 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - April 20, 2015 Category: Hematology Authors: Ponto KA, Elbaz H, Peto T, Laubert-Reh D, Binder H, Wild PS, Lackner K, Pfeiffer N, Mirshahi A Tags: J Thromb Haemost Source Type: research

Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
In conclusion, in daily care, AF patients selected for VKA therapy are healthier than those treated with NOAC, demonstrate a high quality of anticoagulant control and very low stroke rates. However, the risk of major VKA bleeding is unacceptably high despite adequate patient selection and INR control and bleeding outcome is poor. PMID: 25994496 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 21, 2015 Category: Hematology Authors: Michalski F, Tittl L, Werth S, Hänsel U, Pannach S, Sahin K, Weiss N, Beyer-Westendorf J Tags: Thromb Haemost Source Type: research

Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.
In conclusion, persistence was significantly higher with NOAC than VKA, and could alone lead to reduced cardioembolic strokes. Increased guideline adherence following NOAC introduction could further decrease AF stroke burden. PMID: 26246112 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - August 6, 2015 Category: Hematology Authors: Martinez C, Katholing A, Wallenhorst C, Freedman SB Tags: Thromb Haemost Source Type: research

Dabigatran use in elderly patients with atrial fibrillation.
Abstract In elderly patients (≥ 75 years), evidence of dabigatran efficacy is lacking and increased vigilance is warranted. We aimed to assess dabigatran effectiveness and safety in elderly patients in real-world practice. We conducted a population-based study using administrative databases, in Quebec (1999-2013). Dabigatran users (110/150 mg) were compared with matched warfarin users with regard to stroke and bleeding events. Age was categorised into < 75 or ≥ 75 years. Propensity score adjusted models were used. The cohort consisted of 15,918 dabigatran users and 47,192 matched warfarin users, with ...
Source: Thrombosis and Haemostasis - September 10, 2015 Category: Hematology Authors: Avgil-Tsadok M, Jackevicius CA, Essebag V, Eisenberg M, Rahme E, Behlouli H, Pilote L Tags: Thromb Haemost Source Type: research

Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
Abstract The non-vitamin K antagonist oral anticoagulants (NOACs) are replacing warfarin for stroke prevention in many patients with nonvalvular atrial fibrillation. Edoxaban, an oral factor Xa inhibitor, is the newest entrant in this class. Results of the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation (ENGAGE AF) study demonstrate that edoxaban is noninferior to warfarin for prevention of stroke and systemic embolic events, and is associated with significantly less major bleeding, including intracranial bleeding, and reduced cardiovascular mortality. With a net clinical benefit ov...
Source: Thrombosis and Haemostasis - October 15, 2015 Category: Hematology Authors: Weitz JI, Eikelboom J Tags: Thromb Haemost Source Type: research

Prevalence of left atrial thrombus in patients with non-valvular atrial fibrillation. A systematic review and meta-analysis of the literature.
Abstract We performed a meta-analysis about the prevalence of left atrial thrombus (LAT) in patients with atrial fibrillation (AF) undergoing trans-esophageal echocardiography (TEE). Studies reporting on LAT presence in AF patients were systematically searched in the PubMed, Web of Science, Scopus and EMBASE databases and the pooled LAT prevalence was evaluated as weighted mean prevalence (WMP). Seventy-two studies (20,516 AF patients) showed a LAT WMP of 9.8 % (95 %CI: 7.6 %-12.5 %). LAT presence was associated with a higher age (mean difference: 2.56, 95 %CI: 1.49-3.62), and higher prevalence of female...
Source: Thrombosis and Haemostasis - November 26, 2015 Category: Hematology Authors: Di Minno MN, Ambrosino P, Dello Russo A, Casella M, Tremoli E, Tondo C Tags: Thromb Haemost Source Type: research

Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
Abstract The effectiveness and safety of rivaroxaban for stroke prevention in atrial fibrillation (SPAF) demonstrated in ROCKET AF needs to be confirmed in daily care. To evaluate effectiveness and safety of rivaroxaban therapy in SPAF patients in daily care, we used data from an ongoing, prospective, non-interventional registry of more than 2700 patients on novel oral anticoagulants in daily care. Between October 1, 2011 and February 28, 2013, a total of 1204 SPAF patients receiving rivaroxaban were enrolled. During a mean follow-up of 796.2 ± 207.3 days, the combined endpoint of stroke/transient ischaemic attac...
Source: Thrombosis and Haemostasis - January 21, 2016 Category: Hematology Authors: Hecker J, Marten S, Keller L, Helmert S, Michalski F, Werth S, Sahin K, Tittl L, Beyer-Westendorf J Tags: Thromb Haemost Source Type: research

Bleeding Risk Assessment in Atrial Fibrillation: Observations on the Use and Misuse of Bleeding Risk Scores.
This article is protected by copyright. All rights reserved. PMID: 27296528 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 13, 2016 Category: Hematology Authors: Lip GY, Lane DA Tags: J Thromb Haemost Source Type: research

Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists.
Abstract In the RE-LY clinical trial, dabigatran presented a better effectiveness/safety profile when compared to warfarin. However, clinical trials are not very representative of the real-world setting. We aimed to assess the performance of dabigatran in real-world patients with atrial fibrillation (AF) by means of a systematic review and meta-analysis of observational comparison studies with vitamin K antagonists (VKA). We searched PubMed, Embase and Scopus databases until November 2015 and selected studies according to the following criteria: observational study performed with nonvalvular AF patients; reporting...
Source: Thrombosis and Haemostasis - July 27, 2016 Category: Hematology Authors: Carmo J, Moscoso Costa F, Ferreira J, Mendes M Tags: Thromb Haemost Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13